Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses
Abstract
Cancer vaccines targeting nonmutated proteins elicit limited type I T-cell responses and can generate regulatory and type II T cells. Class II epitopes that selectively elicit type I or type II cytokines can be identified in nonmutated cancer-associated proteins. In mice, a T-helper I (Th1) selective insulin-like growth factor binding protein-2 (IGFBP-2) N-terminus vaccine generated high levels of IFNγ secreting T cells, no regulatory T cells, and significant antitumor activity. We conducted a phase I trial of T-helper 1 selective IGFBP-2 vaccination in patients with advanced ovarian cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-1579
Entities
People
- Andrew Coveler
- Angela Kask
- Denise L. Cecil
- Doreen M. Higgins
- Jennifer S. Childs
- John B Liao
- Mary L. Disis
- Yi Yang
- Yushe Dang
Organizations
- Blueprint for Neuroscience Research
- United States Department of Defense
- University of Washington